MARY ACOSTA: Open Payments
NPI 1356759153 · SHREVEPORT, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$339 in 17 payments from 6 companies in 2025. Trend: 2023 $241 · 2024 $212 · 2025 $339
Food & beverage: $339
| Company | Payments | Amount |
|---|---|---|
| Sumitomo Pharma America, Inc. | 5 | $114 |
| Astellas Pharma US Inc | 5 | $81 |
| MILLICENT US INC | 2 | $43 |
| MAYNE PHARMA COMMERCIAL LLC | 2 | $43 |
| Organon LLC | 2 | $39 |
| Evofem Biosciences, Inc. | 1 | $19 |
Products named: MYFEMBREE, Veozah, NEXPLANON, FEMLYV, INTRAROSA, Phexxi.
Industry payments across LA — which companies pay providers there.
